Novo Nordisk CEO Says Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide; When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity For Obesity Drug; Pleased With The Catalent Acquisition Th